Triple-negative breast cancers (TNBC) have an aggressive phenotype with a relatively high rate of recurrence and poor overall survival. To date, there is no approved targeted therapy for TNBC. Aurora kinases (AK) act as regulators of mammalian cell division. They are important 5 for cell cycle progression and are frequently overexpressed or mutated in human tumors, including breast cancer. In this study we investigated the therapeutic potential of targeting AK in preclinical models of human breast cancers, using a pan-inhibitor of AK, AS703569. In vitro, AS703569 was tested in 15 human breast cancer cell lines. TNBC cell lines were more sensitive to AS703569 than were other types of breast cancer cells. Inhibition of proliferation 10 was associated to cell-cycle arrest, aneuploidy and apoptosis. In vivo, AS703569 administered alone significantly inhibited tumor growth in 7 out of 11 patient-derived breast cancer xenografts. Treatment with AS703569 was associated to a decrease of phospho-histone H3 expression. Finally, AS703569 combined to doxorubicin-cyclophosphamide significantly inhibited in vivo tumor recurrence, suggesting that AK inhibitors could be used both in 15 monotherapy and combination settings. In conclusions, these data indicate that targeting Aurora kinases could represent a new effective approach for TNBC treatment.
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INTRODUCTION
Triple-negative breast cancers (TNBC), which lack expression of estrogen receptors (ER), progesterone receptors (PR) and epidermal growth factor receptor 2 (HER2), account for 15% of breast tumors in Europe and an even higher percentage of breast cancer in women of 5 African descent. TNBC tumors have a relatively high rate of recurrence, distant metastases and poor overall survival (1) . TNBC is responsible for a large proportion of breast cancer deaths, despite its relatively small proportion among all breast cancers, due to its generally aggressive clinical course. The standard of care is chemotherapy, although recent research suggests a sound rationale for the use of targeted agents with antitumor and/or antiangiogenic 10 activity such as receptor tyrosine kinase inhibitors. The absence of tumor-specific treatment options in this cancer subset underscores the critical need to develop a better understanding of the biology of this disease, as well as to advance treatment strategies for these patients (1) .
Signaling pathway abnormalities commonly reported in TNBC involve the regulatory mechanisms of cellular proliferation, differentiation, p21-mediated cell signaling and G1-S 15 checkpoint controls (2, 3) .
The Aurora kinase (AK) proteins are serine/threonine kinases that act as regulators of mammalian cell division. Aurora-A localizes to centrosomes/spindle poles and is required for spindle assembly, whereas Aurora-B is a chromosome passenger protein required for phosphorylation of histone H3, chromosome segregation and cytokinesis (4-7).
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Aurora A and B have been implicated in tumor formation and progression (6, 8) and are overexpressed in a variety of cell lines (4, 9) . Relatively high expression of Aurora A and B has been shown in small patient cohorts in several tumor types, including breast, lung, colon, prostate, pancreas, liver, skin, stomach, rectum, esophagus, endometrium, cervix, bladder, ovary, and thyroid cancers (4) (5) (6) 10) . In breast cancer, the expression of Aurora kinase A has 25 been found to be predictive of survival in a cohort of more than 600 primary tumors (7) .
Given their pivotal role in mitosis and overexpression in cancers, AKs have become attractive targets. A number of inhibitors displaying differential inhibitory activities toward the three family members have since then been developed and utilized to understand the functional role of AK in mitotic progression. AK inhibitors induce tretrapoloidy and polyploidy as a result of 30 aberrant mitosis. The effect of the AK inhibitors is therefore unique, in that tumour cells do not undergo cell-cycle arrest after drug treatment. Rather, they are catastrophically driven forward and from aberrant mitosis, which leads to cell death.
In vivo studies with several agents targeting AKs have shown promising results, with tumor growth being inhibited in a number of models (8, 11, 12) . The therapeutic potential of Aurorabased targeted therapy is also being assessed in clinical trials (13) , although none of them have specifically addressed triple-negative breast cancers.
In the current studies, we investigated the efficacy of a pan-Aurora kinase inhibitor,
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AS703569 (14), in preclinical models of human breast cancers. We report that AS703569 has a potent anti-tumor activity in TNBC cell lines, associated with endoreduplication and apoptosis. This anti-tumor activity was confirmed in vivo using patient-derived breast cancer xenografts.
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MATERIALS AND METHODS
Compound
Inhibition of Aurora kinases was achieved using the small-molecule pan-Aurora kinase inhibitor, AS703569 (previously named R763), an orally potent ATP competitive inhibitor.
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In vitro biochemical assays demonstrated that AS703569 inhibited Aurora kinases A, B, and C with IC 50 values of 4.0, 4.8, and 6.8 nM, respectively (Fig1A) (14) . The selectivity of AS703569, assessed in a panel of cell-based kinase assays, was previously published (14) .
In vitro experiments were conducted using dilutions from a 2 mmol/L stock of compound dissolved in DMSO. For in vivo studies AS703569 was suspended in sterile 0.9% NaCl 
Human breast cancer cell lines
The following cell lines were obtained from ATCC (American Type Culture Collection):
MDA-MB-468, MDA-MB-231, HCC1143, HCC 1395, HCC38, HCC1419, HCC2218, MDA- The HBCx-17, HBCx-15 and HBCx-8 triple-negative breast cancer cell lines were obtained from 3 patient-derived breast cancer xenografts (15, 16) .
Cell proliferation assay
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The ATPlite assay was used as a surrogate for detection of cell count/proliferation.
Intracellular ATP concentrations were determined using the ATP-lite Luminescence ATP Detection Assay System (Perkin Elmer, Beaconsfield, UK), following manufacturer's instructions. Briefly, cells were incubated in the presence of serial dilutions of AS703569
(range from 0.001 μM to 100 μM). After 96h in culture, the growth medium was replaced 30 with 100ul phosphate buffered saline (PBS). Cell lysis buffer (50 μl) was added and mixed for 5 min., 50 μl of ATP-lite substrate reagent was then added and mixed for 5 min. After incubating 10 min in the dark, plates were measured for luminescence on a Victor-5 1428
Multilabel HTS counter (Perkin Elmer, Waltham, MA). Results were displayed as relative light units.
Cell cycle and apoptosis analysis
Cells were plated on 6-well tissue culture dishes and allowed to grow overnight to a density of In vivo efficacy studies 20 Female Swiss nude mice, 10-week old, were purchased from Charles River (Les Arbresles, France) and maintained under specific pathogen-free conditions. Their care and housing were in accordance with institutional guidelines as put forth by the French Ethical Committee.
Human breast cancer xenografts were established from primary patient's surgical specimens by grafting tumor fragments into the inter-scapular fat pad of nude mice and maintained 
Real-Time PCR Amplification
Extraction of total RNA and synthesis of cDNA were conducted as previously described from Table 1 . The triple-negative cell lines were relatively more sensitive to AS703569, with IC50s 10 between 0.004 and 0.694 μM, whereas the ER+/PR+ and HER2+ cell lines were more resistant to AS703569, with IC50 between 2.52 and 7.37 μM. The difference between these two groups was statistically significant ( Fig. 1B ; unpaired Student t test, p<0.0001). 15 Inhibition of AK B, or both A and B, results in early exit from mitosis without cell division, leading to endoreduplication and polyploidy. The latter is defined as an accumulation in DNA content (>4N). In order to evaluate the association between polyploidy and the anti-tumor activity of AS703569, compound-induced changes in cell cycle progression were investigated in 7 breast cancer cell lines representing different intrinsic sub-types of breast cancer. To test the effects of Aurora kinase inhibition in vivo, the efficacy of AS703569 as a single agent at its maximum tolerated dose (50 mg/kg once a week) was evaluated in 11 human 15 primary breast cancer xenografts (HBCx, 10 of them triple-negative and 1 HER2+), previously characterized for their IHC profile and their response to standard chemotherapies, (15, 16, 20) . AS703569 had significant antitumor activity in 7 xenograft models (40%-80% TGI compared with the vehicle-treated control group, P < 0.005; responders, Table 2 ). Five BC xenograft models were resistant or low responder (TGI not significantly different or lower 20 than 40%). No correlation was found with the expression of proteins involved in the cell cycle control such as PTEN, Rb or P53. One HBC xenograft carried both p53 and BRCA2 mutations (15) and showed a moderate response to AS703569 with a TGI of 40% and a T/C growth delay of 2 fold. Importantly, AS703569 was also active in the xenograft models that were resistant to docetaxel (Table 2 ). An example is illustrated in Figure 2A and Figure 2B: 25 treatment with AS703569 during 6 weeks resulted in TGI of 80% in the HBCx-10 xenograft ( Fig. 2A) , while treatment by Docetaxel (20 mg/kg given every 3 weeks) didn't change the HBCx-10 tumor growth curve (Fig. 2B) . To determine whether the effect of AS703569 in vivo was correlated to the intrinsic expression of AK genes and other mitotic spindle checkpoint genes, RT-PCR analysis were carried out to quantify the expression of AURKA, 30 AURKB, AURKC, PLK1 (polo family protein kinase), TPX2 (microtubule-associated protein homolog), NEK2 (NIMA-related kinase 2) and NDC80 (kinetochore complex component) (Fig. 2C) . The expression of the Myc oncogene was also determined as possible factor related to the resistance to AK inhibitors (21). Results showed that AURKA and AURKB genes were 26) in all xenograft models, showing increased expression of AURKB in low responder/resistant models compared to responders (Fig. 2C , p = 0.0385, unpaired ttest). AURKC was weekly expressed or not expressed (Ct > 32). The expression of PLK1, TPX2, NEK, NDC80 and MYC genes was relatively high in all models, with no significant differences between responder and resistant xenografts (unpaired t-test).
AS703569 induces endoduplication and apoptosis
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on September 25, 2012; DOI: 10.1158/1535-7163.MCT-12-0441-T highly expressed (Ct ∼
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The AS703569 inhibitor induces a strong and reversible reduction of phosphorylated histone H3 levels in vivo.
To evaluate the pharmacodynamics of AS703569 in vivo, we measured the levels of phosphorylated histone H3 (pHisH3) in 3 BC xenografts as a measure of Aurora kinase B 25 We next addressed the question whether Aurora kinase inhibition could prevent tumour recurrence after conventional therapy, using the HBCx-10 xenograft which is sensitive to AC and has a high frequency of tumor relapse (22) . In the control group, mice were treated with one administration of AC (adryamicin 2mg/kg, cyclophosphamide 100mg/kg), and by Day 60, 7/10 animals showed complete tumor regression as observed by local palpation (Fig. 4A) . In 30 the control group, one mouse was euthanized during tumor remission for histological analysis and 9 animals were followed and tumor regrowth was monitored until ethical euthanasia. In the second group, mice were treated with one administration of AC followed by 8 (Fig. 4B) demonstrates that mice treated with AC alone (n=10, black line) have decreased survival compared to mice treated with AC and AS703569 (n=7, red line). Histological analysis of the mouse inter-scapular fad pad (group AC alone) euthanized during tumor remission revealed the presence of numerous small islands of tumor cells (Fig. 4C) , as confirmed by in situ 5 hybridization with a specific human Alu probe (Fig. 4D and 4E ). To determine whether these residual tumor cells were resting or proliferating cells, we performed Ki67 staining, which showed a relatively high proliferation status of the cancer cells (Fig. 4F and 4G ).
Inhibition of tumor recurrence in a basal-like breast cancer xenograft
Immunostaining for pHisH3 (Fig. 4H and 4I ) revealed that expression in these residual cells was similar to that seen in the HBCx-10 xenograft before chemotherapy (Fig. 3D) , indicating 10 Aurora kinase activity in residual cancer cells. One mouse in the AC+ AS703569 group was submitted for histological examination of the inter-scapular fad pad at day 305 (Fig. 4J) . The analysis revealed the presence of a small fibrous nodule containing several necrotic and mineralized foci within the fad pad with no residual tumor cells as confirmed by a negative Alu staining (Fig. 4K) . Necrotic areas were surrounded by a rim of lipofuscin-containing 15 mouse macrophages (Fig. 4L) . This sensitivity was not dependent on p53 status, in line with a previous report of in vitro sensitivity of lung, colon and prostate cancer cell lines to AS703569 (14) . No correlation with Aurora kinases and Ki67 expression was observed (data not shown). In a previous study, the 10 activity of an AK B inhibitor (AZD1152) in human breast cancer cell lines was reported, with no selective anti-tumor activity for triple-negative cells (23) . Our date indicate that both triplenegative and ER+ cell lines exposed to AS703569 showed endoreduplication, while induction of apoptosis seemed to be greater in the triple-negative cells (from 50% to 80%). The mechanisms of the AS703569 poor activity in HER2 or ER+ cells in vitro are unknown and 15 could be related to genes differentially expressed within the panel of breast cancer cell lines.
Another possibility regarding the sensitivity of TNBC cell lines to AS703569 may, in part, be due to an off-target effect of the compound.
As for the cell lines, the sensitivity to Aurora kinase inhibition in vivo did not appear to be dependent on p53 mutational status. This relationship is not completely discerned in the 20 literature, with different results being reported depending on tumor cell type and the AK inhibitor employed. Cells compromised for p53-checkpoint function were more likely to induce endoreduplication and apoptosis in response to the inhibitor VX-680 (24) . Conversely, leukemia cell lines with wild-type p53 were more sensitive to the AK inhibitor ZM447439 than cell lines with mutant p53, suggesting that a p53-dependent post-mitotic checkpoint may 25 be important in determining cell fate after exposure to AK inhibition (25) . This question has not been specifically addressed in the literature for breast cancers. Interestingly, the HBCx-17 xenograft which carries mutations in both p53 and BRCA2 genes (15) was moderately sensitive to AS703569, suggesting that a combination of these factors might not be sufficient to increase sensitivity to AK inhibitors, as it was demonstrated in vitro (26) .
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General mechanisms of tumor cell resistance to AK inhibitors have not been identified yet, although in vitro studies suggest that mutations of the targeted AKs and overexpression of drug-resistance genes may be involved (27, 28 The absence or low response observed in 4 xenograft models cannot be related to the PgP expression, as none of the models tested in this study express the MDR1 gene. As Aurora kinases are known to be dramatically up-regulated in highly proliferating cells, the proliferation rate of the tumour (that is, the number of mitotic cells exposed to Aurora-kinase inhibition) could potentially determine sensitivity. Our data indicate that a high proliferation 5 index alone is not sufficient to determine sensitivity to AS703569 and that other genes/pathway may be more important in regulating the response to AKs inhibition.
Importantly, AS703569 was effective in models resistant to docetaxel, indicating the therapeutic potential of targeting the Aurora kinase family in this subtype of tumors, especially recurring or advanced breast cancers.
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One of the key effector proteins regulated by Aurora B kinase is the RB1 protein (29) .
However the RB1 protein expression was not related to the in vivo response of the AS703569 inhibitor in this study, which is in line with previous reports showing that RB1 status alone does not correlate with sensitivity to Aurora kinase inhibitors in vivo (21, 30). The finding that AK genes A and B were highly expressed in breast cancer xenografts is consistent with Consistent with other studies, pHisH3 reduction was rapid and reversible (31, 32) .
Interestingly, pHisH3 reduction was also observed in a xenograft model that did not respond to AS703569, suggesting that inhibition of AK activity alone may not be sufficient to arrest 25 cell proliferation in resistant tumors and these might escape treatment through alternative pathways. In addition, this result suggests that a decreased expression of pHisH3, the phenotype of Aurora B inhibition, is not predictive of tumor response in vivo.
In the responding tumor xenograft models, tumor growth was not completely abolished, despite the strong inhibition of pHisH3 induced by AS703569. This is consistent with other 
